文献速递胸部肿瘤头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

干扰素ε缺失是9p21与免疫冷肿瘤、免疫检查点治疗耐药及内源性CXCL9/10诱导之间难以捉摸的联系

Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.
PubMed 文献 · J Thorac Oncol · 2024-12-24

该研究整合13项报告、36个免疫检查点治疗(ICT)队列的临床数据及人肿瘤、细胞系和小鼠模型实验,探究9p缺失通过干扰素(IFN)-I(主要为IFNε)导致免疫逃逸的机制。结果显示9p拷贝数缺失与免疫冷、ICT耐药相关;IFNε是9p21.3细胞内在IFN-I信号,连接CD8 T细胞抑制与CXCL9/10表达;9p缺失肿瘤中内源性CXCL9/10诱导能力缺失,据此设计了DC-CXCL9/10疫苗。

要点

  • 9p(9p21.3、9p24.1)拷贝数缺失与免疫冷、程序性细胞死亡蛋白1轴ICT耐药相关。
  • 在HPV阴性头颈鳞癌中,IFNE是肿瘤和细胞系中表达最高的IFN-I基因,受9p21.3驱动并在9p缺失时受抑制。
  • 9p21.3缺失深度渐进与IFNE及CXCL9/10-CXCR3抑制渐进相关。

核心结论

  • IFNε是9p21细胞内在IFN-I信号,连接人CD8 T细胞、髓系DC、CXCL9/10及小鼠DC和巨噬细胞亚型/亚群Cxcl9/10表达。
  • 9p缺失的IFN-I和IFN-γ通路(如JAK2)基因在p21和p24缺乏免疫荒漠、ICT耐药状态下内源性CXCL9/10诱导能力。

研究设计与样本

  • 更新并阐明快速出现的临床9p ICT队列数据,并开展人肿瘤、细胞系和小鼠模型内在9p、IFN-I及肿瘤免疫微环境CXCL9/10的解卷积、中介和实验研究。
  • 分析CXCL9/10-CXCR3细胞来源及其受9p缺失(大小和深度)调控,以及小鼠空间单细胞RNA测序(scRNA-seq)同线性chr4qC4 IFN-I(ΔS与ΔL免疫逃逸模型)的免疫细胞类型、亚型及亚群Cxcl9/10+数量、比例和每细胞表达。
  • 临床部分纳入13项报告、36个ICT队列,时间<4年。

主要发现

  • 9p(9p、9p21.3、9p24.1)拷贝数缺失与免疫冷、程序性细胞死亡蛋白1轴ICT耐药的人乳头瘤病毒阴性头颈鳞癌、非鳞NSCLC、黑色素瘤、尿路上皮癌和间皮瘤相关(13项报告,36个ICT队列;<4年)。
  • 在HPV阴性头颈鳞癌中,IFNE是肿瘤和细胞系中表达最高(且在9p缺失时受抑制)的IFN-I基因,由9p21.3驱动(q=0.03;对比9p24.1,q=0.27);与效应T细胞抑制直接相关(CD8最强,p=0.006;中介分析),呈现显著TP53突变共现和IFN应答通路耗竭。
  • 9p21.3缺失深度渐进(野生型、浅、深)与IFNE和CXCL9/10-CXCR3抑制渐进相关;9p21.3 ΔS(对比ΔL)IFN-I对CD8、NK(CD4、B、CD103)水平的影响。
  • 泛肿瘤IFNE缺失/肿瘤免疫微环境模式具有 profound 组织特异性(34种肿瘤类型中4种Z≤1.95)。
  • IFN完整的ΔS(对比ΔL)KPC胰腺模型与Cxcl9/10+树突状细胞(DC)、巨噬细胞和中性粒细胞数量相关(在KPL-3M非鳞NSCLC中确认),并与巨噬细胞每细胞表达相关;DC和巨噬细胞亚聚类显示M1、Ccl5和常规1型DC(cDC1)水平异质性,在ΔS中尤其高。

关键数值与推荐

  • 在HPV阴性头颈鳞癌中,IFNE由9p21.3驱动(q=0.03;对比9p24.1,q=0.27)。
  • IFNE与效应T细胞抑制直接相关,CD8最强(p=0.006;中介分析)。
  • 泛肿瘤IFNE缺失/肿瘤免疫微环境模式组织特异性:34种肿瘤类型中4种Z≤1.95。

临床怎么用

  • 这些发现、9p缺失/ICT耐药数据及DC疫苗肺部试验已促成DC-CXCL9/10疫苗设计,旨在绕过9p缺失肿瘤中严重的趋化因子缺陷。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Copy number alterations of chromosome 9p, or parts thereof, impair immune response and confer immune-checkpoint therapy (ICT) resistance by direct elimination of immune-regulatory genes on this arm, notably interferon (IFN)-γ (at 9p24.1) and type I IFN (IFN-I) cluster (9p21.3) genes. Nevertheless, the primary 9p-loss human tumor immune readout is indirect (CXCL9/10 depletion at 4q21.1), and molecular alteration of chromosomes with engineered tandem elements-engineered 9p21.3-syntenic deletions in mice, Cdkn2a/b±Mtap (ΔS) versus larger Cdkn2a/b+Mtap+IFN-I (ΔL), revealed the causal link of IFN-I, primarily IFNϵ, to immune evasion. METHODS: This report updates and explicates the rapidly emerging body of clinical 9p ICT-cohort data and executes human (tumor, cell line) and mouse-model intrinsic 9p, IFN-I, and tumor-immune microenvironment CXCL9/10 deconvolution, mediation, and experimental studies. We analyzed CXCL9/10-CXCR3 cell sources and regulation by 9p deletion (size and depth) and mouse spatial single-cell RNA sequencing (scRNA-seq) syntenic chr4qC4 IFN-I (ΔS versus ΔL immune-evasive model) studies of immune-cell type, subtype, and subcluster Cxcl9/10+ numbers, fractions, and per-cell expression. RESULTS: Chr9p (9p, 9p21.3, 9p24.1) copy number loss is associated with immune-cold, programmed cell death protein 1 axis ICT-resistant human papillomavirus-negative head and neck squamous cancer, nonsquamous NSCLC, melanoma, urothelial cancer, and mesothelioma (13 reports, 36 ICT cohorts; <4 y). IFN-I has been associated with IFNα and ICT resistance. In human papillomavirus-negative head and neck squamous cancer, IFNE was the most highly expressed (and suppressed in 9p loss) IFN-I gene in tumors and cell lines, driven by 9p21.3 (q = 0.03; versus 9p24.1, q = 0.27); direct link to effector T-cell suppression (CD8 strongest, p = 0.006; mediation analysis), exhibited striking TP53 mutation co-occurrence and IFN-response pathway depletion. Progressively deep 9p21.3 loss (wild-type, shallow, deep) correlated with progressive IFNE and CXCL9/10-CXCR3 suppression; 9p21.3 ΔS (versus ΔL) IFN-I impact on CD8, NK (CD4, B, CD103) levels. Pan-tumor IFNE loss/tumor-immune microenvironment patterns were profoundly tissue-specific (Z ≤ 1.95 in 4/34 tumor types). IFN-intact ΔS (versus ΔL) KPC pancreatic model was linked to Cxcl9/10+ dendritic cell (DC), macrophage, and neutrophil number (confirmed in KPL-3M nonsquamous NSCLC), and macrophage per-cell expression. DC and macrophage subclustering revealed heterogeneity at the level of M1, Ccl5, and conventional type 1 DC (cDC1), particularly high in ΔS. CONCLUSION: IFNϵ is the elusive, cell-intrinsic 9p21 IFN-I signal to human CD8 T-cell, myeloid DC, CXCL9/10, murine DC, and macrophage subtype and subcluster Cxcl9/10 expression. 9p-loss IFN-I and IFN-γ pathway (e.g., JAK2) genes at p21 and p24 lack the capacity of endogenous CXCL9/10 induction in an immune-desert, ICT-resistant state. These findings, 9p-loss/ICT-resistance data, and DC vaccine lung trials have led to a DC-CXCL9/10 vaccine, designed to bypass the severe chemokine deficit in 9p-loss tumors.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao X, Liu B, William WN, et al. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction. J Thorac Oncol. 2024. PMID: 39725169. doi:10.1016/j.jtho.2024.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。